Ben joined Pivotal bioVenture Partners in 2021. Prior to joining Pivotal, Ben was a life sciences transactions attorney at Cooley for four years, providing strategic advice and negotiating partnering and licensing deals on behalf of private and public biotechs across multiple therapeutic areas and modalities. Representative clients included 23andMe, Arcus, Arsenal, Bicycle, BioMarin, Forty Seven, Horizon, MacroGenics, Senti, Roivant, among others, with aggregate transaction value of more than $8 billion. Before joining Cooley, Ben was a patent advisor at Wilson Sonsini Goodrich & Rosati, where he designed, prosecuted, and managed the patent portfolios for biotech startups in the pharmaceutical, biological and diagnostic sectors. Ben earned his JD from the University of California, Berkeley, School of Law (Boalt Hall), his PhD in chemical biology from the California Institute of Technology under the mentorship of Professor Peter Dervan, and his BA in biochemistry from Columbia University. He is a co–author of 10 peer–reviewed scientific publications.
